Cargando…

Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats

Oral delivery of therapeutic peptides has been a daunting challenge due to poor transport across the tight junctions and susceptibility to enzymatic degradation in the gastrointestinal tract. Numerous advancement in nanomedicine has been made for the effective delivery of protein and peptide. Owing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jian-Miao, Wu, Lin-Jie, Lin, Meng-Ting, Lu, Yi-Ying, Wang, Tian-Tian, Han, Min, Zhang, Bin, Xu, Dong-Hang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183037/ https://www.ncbi.nlm.nih.gov/pubmed/35683851 http://dx.doi.org/10.3390/polym14112181

Ejemplares similares

Correction: Yang et al. Construction and Evaluation of Chitosan-Based Nanoparticles for Oral Administration of Exenatide in Type 2 Diabetic Rats. Polymers 2022, 14, 2181
por: Yang, Jian-Miao, et al.
Publicado: (2023)

Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide
por: Abeer, Muhammad Mustafa, et al.
Publicado: (2019)

Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice
por: Shi, Yanan, et al.
Publicado: (2018)

An experimental study of exenatide effects on renal injury in diabetic rats
por: Wang, Xiaodong, et al.
Publicado: (2019)

Influence of chitosan coating on the oral bioavailability of gold nanoparticles in rats
por: Alalaiwe, Ahmed, et al.
Publicado: (2019)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Author Correction: Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice
por: Shi, Yanan, et al.
Publicado: (2023)

Evaluation of the Safety and Gastrointestinal Migration of Guanidinylated Chitosan after Oral Administration to Rats
por: Khan, Nowshin Farzana, et al.
Publicado: (2023)

Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models
por: Fu, Zhenhong, et al.
Publicado: (2020)

Exenatide promotes regeneration of injured rat sciatic nerve
por: Kuyucu, Ersin, et al.
Publicado: (2017)

Recent advances of chitosan nanoparticles as drug carriers
por: Wang, Jun Jie, et al.
Publicado: (2011)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles
por: Ballarín-González, Borja, et al.
Publicado: (2013)

The Acute Effects of Oral Administration of Phytic Acid-Chitosan-Magnetic Iron Oxide Nanoparticles in Mice
por: Mohd Tamsir, Norain, et al.
Publicado: (2019)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Chitosan Nanoparticles as Oral Drug Carriers
por: Guadarrama-Escobar, Omar Rodrigo, et al.
Publicado: (2023)

In vivo antitumor effects of carboxymethyl chitosan-conjugated triptolide after oral administration
por: Zeng, Huahui, et al.
Publicado: (2020)

Controlled release of silica-coated insulin-loaded chitosan nanoparticles as a promising oral administration system
por: Fathy, Mohamed M., et al.
Publicado: (2023)

Synthesis, Characterization of Low Molecular Weight Chitosan Selenium Nanoparticles and Its Effect on DSS-Induced Ulcerative Colitis in Mice
por: Peng, Shu-Jiang, et al.
Publicado: (2022)

Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice
por: Bao, Xiaoyan, et al.
Publicado: (2020)

Chitosan nanoparticles for oral drug and gene delivery
por: Bowman, Katherine, et al.
Publicado: (2006)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

Oral Delivery of Exenatide via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate
por: Zhang, Baojie, et al.
Publicado: (2014)

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
por: Tatarkiewicz, K, et al.
Publicado: (2013)

Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats
por: Fujita, Shunsuke, et al.
Publicado: (2015)

Interpretation the Hepatotoxicity Based on Pharmacokinetics Investigated Through Oral Administrated Different Extraction Parts of Polygonum multiflorum on Rats
por: Zhang, Miao, et al.
Publicado: (2018)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Extended Exenatide Administration Enhances Lipid Metabolism and Exacerbates Pancreatic Injury in Mice on a High Fat, High Carbohydrate Diet
por: Rouse, Rodney, et al.
Publicado: (2014)

Exenatide Activates the APPL1-AMPK-PPARα Axis to Prevent Diabetic Cardiomyocyte Apoptosis
por: XiaoTian, Lei, et al.
Publicado: (2016)

Can TiC nanoparticles produce toxicity in oral administration to rats?
por: Laloy, Julie, et al.
Publicado: (2014)

Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart
por: Ding, Wei, et al.
Publicado: (2019)

Preparation of Puerarin Chitosan Oral Nanoparticles by Ionic Gelation Method and Its Related Kinetics
por: Yan, Jie, et al.
Publicado: (2020)

Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress
por: Nomura, Satoshi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qppbvs4hj5ft5ohhsrlstbp85j